title: Systemic cyclosporine A in severe atopic keratoconjunctivitis.
abstract: OBJECTIVE
  Atopic keratoconjunctivitis (AKC) is a potentially blinding disease. It is usually associated with atopic dermatitis that has been managed successfully with systemic cyclosporine A (CSA) in some severe forms of the disease. In this study, the authors evaluated systemic CSA therapy in patients with severe AKC.
  
  
  METHODS
  Cohort Retrospective study.
  
  
  METHODS
  Four patients aged 31 to 64 with severe AKC and atopic dermatitis refractory to or dependent on steroid therapy.
  
  
  METHODS
  The patients received oral CSA.
  
  
  METHODS
  Ocular inflammation, skin condition, CSA treatment methods (dosage, duration), CSA-related side effects.
  
  
  RESULTS
  Daily dosage of oral CSA was 3 to 5 mg/kg and mean duration of treatment was 37 months (range, 22-48 months). Ocular inflammation was controlled totally in three patients. One patient responded only partially to treatment. Side effects included renal toxicity in one patient. Reduction of CSA dosage resulted in normalization of serum creatinine level.
  
  
  CONCLUSIONS
  This report suggests that systemic CSA represents an interesting alternative therapy in severe AKC.
authors.affiliation: Department of Ophthalmology, Hospital Bichat, Paris, France.
authors.forename: T
authors.initials: T
authors.lastname: Hoang-Xuan
authors.forename: O
authors.initials: O
authors.lastname: Prisant
authors.forename: D
authors.initials: D
authors.lastname: Hannouche
authors.forename: H
authors.initials: H
authors.lastname: Robin
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000473:pathology; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications* / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007634:Keratitis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D007668:Kidney / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011241:Prednisone